Leerink Swann today maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $271. Biogen reported strong ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE